Related Experiment Videos
The morbidity of bone disease in thalassemia
1Department of Hematology/Oncology, Children's Hospital Oakland, California 94609, USA. evichinsky@lanminds.com
Insights
Thalassemia patients face significant bone disease risks, including osteoporosis and fractures. Annual screening and interventions like bisphosphonates can prevent long-term complications and improve bone health.
Area of Science:
- Hematology
- Endocrinology
- Orthopedics
Background:
- Bone disease is a major cause of morbidity in aging thalassemia patients.
- Complications include osteoporosis, fractures, scoliosis, and nerve compression.
- Etiologies are multifactorial, involving hormonal, nutritional, and treatment-related factors.
Purpose of the Study:
- To highlight the risks and complications of bone disease in thalassemia.
- To emphasize the importance of early detection and intervention.
- To discuss preventive strategies and treatment options.
Main Methods:
- Review of existing literature on thalassemia-related bone disease.
- Analysis of risk factors, including age, hemoglobin levels, puberty, hormonal status, and iron stores.
- Evaluation of treatment outcomes for bisphosphonates, calcitonin, estrogen, and testosterone.
Main Results:
- Bone disease presentation varies from asymptomatic to severe fractures and neurological issues.
- Risk factors like older age, low hemoglobin, delayed puberty, and high iron stores increase susceptibility.
- Bisphosphonates show rapid healing, calcitonin treats osteopenia, and hormone replacement lowers risk in select patients.
Conclusions:
- Annual screening for bone disease is crucial for early detection and prevention of long-term morbidity.
- Multifactorial interventions, including bisphosphonates and hormone therapy, can effectively manage bone disease.
- Patient education on risk factors and symptoms is vital for both transfused and non-transfused individuals.
Abstract:
As thalassemia patients age, bone disease becomes a serious cause of morbidity. The frequency and type of bone disease is affected by the underlying type of thalassemia and its treatment. Problems include rickets, scoliosis, spinal deformities, nerve compression, fractures and severe osteoporosis. In early stages, patients may be asymptomatic but can present with back pain, a limp, dyspnea, neurological emergencies, or sudden fractures. The etiologies are often multifactorial, culminating with increased bone resorption and remodeling. They include hormonal deficiency, bone marrow expansion, nutritional deficiency, or desferal toxicity. Particular risk factors include older patients, low baseline hemoglobin, delayed puberty, hormonal failure, and high iron stores. Nutritional deficiencies may further compound the patient's risk for bone disease. Increasing evidence suggests that these complications and their associated long-term morbidity can be prevented if an annual screening is done, followed by long-term intervention. Patients treated with amino biphosphonates inhibit bone resorption and may demonstrate rapid healing. Intra-nasal calcitonin has also been successful in treating osteopenia. Early use of estrogen and testosterone appears to markedly lower the risk for selective patients. Both transfused and non-transfused patients should be educated about risk factors and early symptoms. All patients should be screened annually for bone disease. Once adolescence occurs, annual testing in selected cases should include bone density studies with X-ray absorptiometry.